Question to the Department of Health and Social Care:
To ask Her Majesty's Government how many patients in the UK are being treated with (1) Paxlovid, and (2) Sotrovimab; and what is their strategy for the wider deployment of these antiviral treatments for COVID-19.
The information requested is not held centrally. However, as of 31 March 2022, 5,443 patients in England had received the oral antiviral treatment Paxlovid since it was first available in the National Health Service on 10 February 2022. Since 20 December 2021, 18,468 patients in England have received the intravenous monoclonal antibody sotrovimab.
Further evidence on the effectiveness of antiviral treatments is needed to support decisions on any wider deployment. This includes findings of the PANORAMIC study and international trial evidence. PANORAMIC is a primary care-based study for oral antivirals such as molnupiravir and Paxlovid. The RECOVERY trial is studying both sotrovimab and Paxlovid as potential future treatments for patients hospitalised due to COVID-19.